Categories: All postsCannabis

Acreage Holdings has 63 per cent upside, Beacon Securities says

With the purchase of a vertically integrated medical marijuana operation in the major market state of Michigan, US cannabis company Acreage Holdings  (Acreage Holdings Stock Quote, Chart CSE:ACRG.U) should have a head start on the competition in the state’s newly opened up rec cannabis market, says analyst Russell Stanley of Beacon Securities, who on Monday reiterated his “Buy” rating and 12-month target price of $40.00. (All figures in US dollars.)

Yesterday, New York-based Acreage announced an agreement to acquire the real estate assets of Michigan-based Blue Tire Holdings, which will include a 55,000 sq. ft. facility in Flint that will be used for cultivation, manufacturing and packaging and will also serve as Acreage’s flagship retail location in the state, which will open its rec cannabis market on December 6.

Stanley, who has already factored in the Blue Tire purchases into his estimates but nonetheless views the announcement as a positive, says that Michigan has been an overlooked market opportunity.

“Michigan’s medical program was established in 2008, and it now has approximately 300k registered patients, making it the 2nd largest in the United States. However, it has traditionally been a caregiver-based program, and a framework for a regulated commercial industry was only passed in 2016, so commercial licensing is still in its early days,” Stanley says.

“[The approved Proposal 1 vote] requires the state to begin accepting applications for recreational dispensaries within 12 months, and we expect existing medical providers to have a significant head start over new entrants,” he says.

Stanley expects Acreage to generate revenue and Adj. EBITDA in fiscal 2018 of $69 million and negative $13 million, respectively, revenue and Adj. EBITDA in fiscal 2019 of $272 million and $60 million, respectively, and revenue and Adj. EBITDA in fiscal 2020 of $533 million and $158 million, respectively.

The analyst’s $40.00 target represented a return of 63 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: acrg.u
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

4 days ago